Exact Sciences Corp. wants to raise $50 million to get its test for colon cancer ready to go to market, even though it will be more than a year before that happens, in the best of circumstances.
“Part of the thinking behind that decision has to be a reflection of their concerns about the general stock market overall,” said Brian Hellmer, director of the Hawk Center for Applied Security Analysis at the UW-Madison School of Business.